86 Publications (Page 2 of 4)
2008
A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer
Robertson, Michael JKirkwood, John MLogan, Theodore FKoch, Kevin MKathman, StevenKirby, Lyndon CBell, William NThurmond, Linda MWeisenbach, Jill and Dar, Mohammed M
Clinical Cancer Research, vol. 14, (no. 11), pp. 3462-3469, 2008. | Journal Article
2007
Evaluation of the Immunological Effects of Cytokines Administered to Patients With Cancer
Robertson, Michael J
Methods in Pharmacology and Toxicology, pp. 297-317, 2007. | Journal Article
 
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson, Michael JKahl, Brad SVose, Julie Mde Vos, SvenLaughlin, MaryFlynn, Patrick JRowland, KendrithCruz, Jose CGoldberg, Stuart LMusib, LunaDarstein, ChristelleEnas, NathanKutok, Jeffery LAster, Jon CNeuberg, Donna SSavage, Kerry JLa Casce, Ann SThornton, DonaldSlapak, Christopher A and Shipp, Margaret A
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 25, (no. 13), pp. 1741-6, 2007/May/1. | Journal Article
2006
Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer
Robertson, Michael JMier, James WLogan, Theodore FAtkins, Michael BKoon, Henry BKoch, Kevin MKathman, StevenPandite, Lini NOei, CoreenKirby, Lyndon CJewell, Roxanne CBell, William NThurmond, Linda MWeisenbach, JillRoberts, Suzanne and Dar, Mohammed M
Clinical Cancer Research, vol. 12, (no. 14), pp. 4265-4273, 2006. | Journal Article
 
Interleukins 18 and 21: biology, mechanisms of action, toxicity, and clinical activity.
Logan, Theodore F and Robertson, Michael J
Current oncology reports, vol. 8, (no. 2), pp. 114-9, 2006/Mar. | Journal Article
 
Macrophage activation syndrome and other systemic inflammatory conditions after BMT
Sreedharan, A.Bowyer, S.Wallace, C. ARobertson, Michael JSchmidt, K.Woolfrey, A. E and Nelson, Robert P
Bone Marrow Transplantation, vol. 37, (no. 7), pp. 629-34, Apr 2006. | Journal Article
 
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher, Richard IBernstein, Steven HKahl, Brad SDjulbegovic, BenjaminRobertson, Michael Jde Vos, SvenEpner, ElliotKrishnan, AmritaLeonard, John PLonial, SagarStadtmauer, Edward AO'connor, Owen AShi, HongliangBoral, Anthony L and Goy, André
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 24, (no. 30), pp. 4867-74, 2006/Oct/20. | Journal Article
 
Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis.
Ganjoo, KristenAn, Caroline SRobertson, Michael JGordon, Leo ISen, Joy AWeisenbach, JillLi, ShuliWeller, Edie AOrazi, Attilio and Horning, Sandra J
Leukemia & lymphoma, vol. 47, (no. 6), pp. 998-1005, 2006/Jun. | Journal Article
 
The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy.
Starnes, TrevorStarnes, T.Rasila, Kanwaldeep KRasila, K.K.Robertson, Michael JRobertson, M.J.Brahmi, ZacharieBrahmi, Z.Dahl, RichardDahl, R.Christopherson, KentChristopherson, K.Hromas, Robert and Hromas, R.
Experimental hematology, vol. 34, (no. 8), pp. 1101-5, 2006/Aug. | Journal Article
2005
A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.
Ganjoo, KristenGanjoo, Kristen NRobertson, Michael JRobertson, Michael JFisher, WilliamFisher, WilliamJung, Sin HoJung, Sin-HoMcClean, JohnMcClean, JohnHuh, Sang YoonHuh, Sang YBufill, JoseBufill, JoseWilliams, SheronWilliams, SheronCripe, Larry D and Cripe, Larry D
American journal of clinical oncology, vol. 28, (no. 2), pp. 169-72, 2005/Apr. | Journal Article
 
Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Robertson, Michael JAbonour, RafatHromas, Robert ANelson, Robert PFineberg, Naomi S and Cornetta, Kenneth G
Leukemia & lymphoma. , vol. 46, (no. 10), pp. 1477-87, 2005/Oct. | Journal Article
 
Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.
Robertson, Michael JChang, Hua-ChenPelloso, David and Kaplan, Mark H
Blood. , vol. 106, (no. 3), pp. 963-70, 2005/Aug/1. | Journal Article
 
Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression
Robertson, Michael JSchacterle, RSMackin, GAWilson, SNBloomingdale, KLRitz, Jerome and Komaroff, Anthony L
Clinical and Experimental Immunology, vol. 141, (no. 2), pp. 326-332, 2005. | Journal Article
2004
Immunological consequences of interleukin 12 administration after autologous stem cell transplantation.
Pelloso, DavidCyran, KatherineTimmons, LynetteWilliams, Brian T and Robertson, Michael J
Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 10, (no. 6), pp. 1935-42, 2004/Mar/15. | Journal Article
 
Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma and Hodgkin's Disease
Younes, AnasYounes, AnasYounes, AnasYounes, AnasYounes, AnasPro, BarbaraPro, BarbaraPro, BarbaraPro, BarbaraPro, BarbaraRobertson, Michael JRobertson, Michael JRobertson, Michael JRobertson, Michael JRobertson, Michael JFlinn, Ian WFlinn, Ian WFlinn, Ian WFlinn, Ian WFlinn, Ian WRomaguera, Jorge ERomaguera, Jorge ERomaguera, Jorge ERomaguera, Jorge ERomaguera, Jorge EHagemeister, FredrickHagemeister, FredrickHagemeister, FredrickHagemeister, FredrickHagemeister, FredrickDang, Nam HDang, Nam HDang, Nam HDang, Nam HDang, Nam HoangFiumara, PaoloFiumara, PaoloFiumara, PaoloFiumara, PaoloFiumara, PaoloLoyer, Evelyne MLoyer, Evelyne MLoyer, Evelyne MLoyer, Evelyne MLoyer, Evelyne MCabanillas, Fernando FCabanillas, Fernando FCabanillas, Fernando FCabanillas, Fernando FCabanillas, Fernando FMcLaughlin, Peter WMcLaughlin, Peter WMcLaughlin, Peter WMc Laughlin, PeterMcLaughlin, Peter WRodriguez, Maria AlmaRodriguez, Maria AlmaRodriguez, Maria AlmaRodriguez, Maria ARodriguez, Maria AlmaSamaniego, FelipeSamaniego, FelipeSamaniego, FelipeSamaniego, Felipe and Samaniego, Felipe
Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 10, (no. 16), pp. 5438, 2004-Aug-15. | Journal Article
2002
Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis.
Starnes, TrevorBroxmeyer, Hal ERobertson, Michael J and Hromas, Robert
Journal of immunology (Baltimore, Md. : 1950), vol. 169, (no. 2), pp. 642-6, 2002/Jul/15. | Journal Article
 
IL-17D, a Novel Member of the IL-17 Family, Stimulates Cytokine Production and Inhibits Hemopoiesis
Starnes, T.Broxmeyer, Hal ERobertson, Michael J and Hromas, R.
Journal of Immunology, vol. 169, (no. 2), pp. 642-646, 2002. | Journal Article
 
Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.
Robertson, MichaelRobertson, MichaelRobertson, Michael JPelloso, DavidPelloso, DavidPelloso, DavidAbonour, RafatAbonour, RafatAbonour, RafatHromas, RobertHromas, RobertHromas, Robert ANelson, RobertNelson, Robert PNelson, RobertWood, LisaWood, LisaWood, LisaCornetta, KennethCornetta, Kenneth and Cornetta, Kenneth
Clinical Cancer Research, vol. 8, (no. 11), pp. 3383-93, 2002/Nov. | Journal Article
 
Role of chemokines in the biology of natural killer cells
Robertson, Michael J
Journal of Leukocyte Biology, vol. 71, (no. 2), pp. 173-183, 2002. | Journal Article
2001
Are natural killer cells the key to treating Epstein-Barr virus-associated lymphoproliferative disorders?
Robertson, Michael J
The Journal of clinical investigation. , vol. 108, (no. 6), pp. 801-2, 2001/Sep. | Journal Article
 
Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production.
Starnes, TrevorStarnes, TStarnes, TrevorRobertson, MichaelRobertson, MichaelRobertson, Michael JSledge, GeorgeSledge, GSledge, GeorgeKelich, StephanieKelich, SKelich, StephanieNakshatri, HarikrishnaNakshatri, HNakshatri, HarikrishnaBroxmeyer, HalBroxmeyer, H EBroxmeyer, HalHromas, RobertHromas, Robert A and Hromas, Robert
Journal of immunology (Baltimore, Md. : 1950), vol. 167, (no. 8), pp. 4137-40, 2001/Oct/15. | Journal Article
 
IL-17F, a Novel Cytokine Selectively Expressed in Activated T Cells and Monocytes, Regulates Angiogenesis and Endothelial Cell Cytokine Production
Starnes, T.Robertson, Michael JSledge, G.Kelich, S.Nakshatri, H.Broxmeyer, HE and Hromas, Robert A
Journal of Immunology, vol. 167, (no. 8), pp. 4137-4140, 2001. | Journal Article
2000
Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells.
Abonour, RafatWilliams, David AEinhorn, Lawrence HHall, K MChen, JCoffman, JTraycoff, C MBank, ArthurKato, IWard, MWilliams, Stephen DHromas, Robert ARobertson, Michael JSmith, Franklin OWoo, DanielMills, BSrour, Edward F and Cornetta, Kenneth G
Nature Medicine, vol. 6, (no. 6), pp. 652-8, 2000/Jun. | Journal Article
 
Regulation of Human Natural Killer Cell Migration and Proliferation by the Exodus Subfamily of CC Chemokines
Robertson, Michael JWilliams, BTChristopherson, Kent WBrahmi, Z. and Hromas, Robert A
Cellular Immunology, vol. 199, (no. 1), pp. 8-14, 2000. | Journal Article
1999
CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor
Borrego, F.Robertson, Michael JRitz, JeromePena, J. and Solana, R.
Immunology, vol. 97, (no. 1), pp. 159-165, 1999. | Journal Article